Triumvira Immunologics Completes Extension Of Series A Financing, For Total Round Of Approximately $100 Million
Round Type
Series A
AustinBiotechnologyHealth CareScience And EngineeringInternet ServicesDescription
Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced the completion of an extension of its Series A financing, bringing the total round to approximately $100 million. The Series A extension featured new investors, including significant participation from B Capital Group, along with ATEM Capital, the Myeloma Investment Fund, the Multiple Myeloma Research Foundation’s venture philanthropy subsidiary, and others, joined by significant participation from existing investors, Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures.
Quick answer
Triumvira Immunologics Inc. raised an undisclosed amount in a Series A round, dated March 17, 2022. Triumvira Immunologics Inc. is based in Austin, Texas, United States.
- How much did Triumvira Immunologics Inc. raise?
- Triumvira Immunologics Inc. raised an undisclosed amount in a Series A round on March 17, 2022.
- What does Triumvira Immunologics Inc. do?
- At Triumvira Immunologics, Inc., our team is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease.
- Where is Triumvira Immunologics Inc. based and how big is it?
- Triumvira Immunologics Inc. is based in Austin, Texas, United States.
- Who are the decision-makers at Triumvira Immunologics Inc?
- Fundz holds 1 contact at Triumvira Immunologics Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Internet Services around the same time
Companies in the same sectors as Triumvira Immunologics Inc. that raised within 45 days of this round, from Fundz verified event records.
- IMPLICITY raised $23M (Funding Round) on April 27, 2022.
- Unlearn raised $50M on April 19, 2022.
- Unlearn raised $50M (Series B) on April 19, 2022.
- Surf Bio raised $16M (Seed) on April 12, 2022.
- Ensem Therapeutics raised $67M (Series A) on April 6, 2022.
- Trait Biosciences Inc. raised $210K (Series A) on April 6, 2022.
Who to call at Triumvira Immunologics Inc., and when
A new round usually means Triumvira Immunologics Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Triumvira Immunologics Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Triumvira Immunologics Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Triumvira Immunologics Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Triumvira Immunologics Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansTriumvira Immunologics Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.